<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="110921">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01872065</url>
  </required_header>
  <id_info>
    <org_study_id>Heparc-1001</org_study_id>
    <nct_id>NCT01872065</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability Study of ARC-520 in Healthy Volunteers</brief_title>
  <official_title>A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ARC-520 in Normal Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arrowhead Research Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arrowhead Research Corporation</source>
  <oversight_info>
    <authority>Australia: Human Research Ethics Committee</authority>
    <authority>Australia: Department of Health and Ageing Therapeutic Goods Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of
      ARC-520 in normal, adult volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>To determine the incidence and frequency of adverse events as a measure of safety and tolerability of ARC-520</measure>
    <time_frame>One month</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The incidence and frequency of adverse events (AEs), serious adverse events (SAEs), related AEs, related SAEs, and AEs leading to withdrawal, dose modification, or treatment discontinuation will be summarized by dose and treatment group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the pharmacokinetics of ARC-520 at different dose concentrations</measure>
    <time_frame>2 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Plasma concentrations following a single dose of ARC-520 at different dose levels will be used to calculate the following ARC-520 pharmacokinetic parameters:  Cmax, tmax, AUC0-24, AUCinf, and t1/2.  Descriptive statistics of pharmacokinetic parameters will include mean, standard deviation, and coefficient of variation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>ARC-520</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose, intravenous administration of ARC-520.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose, intravenous administration of Normal Saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARC-520</intervention_name>
    <arm_group_label>ARC-520</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Normal Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Healthy male or female subjects, 18-55 years of age

          -  Be a non-smoker

        Key Exclusion Criteria:

          -  History of clinically relevant medical illnesses that in the Investigator opinion may
             jeopardize subject safety or interfere with participation in the study, including but
             not limited to hematological, renal, endocrine, pulmonary, gastrointestinal,
             cardiovascular, hepatic, psychiatric, neurologic, or allergic disease

          -  Acute signs of hepatitis/other infection (e.g., moderate fever, jaundice, nausea,
             vomiting, abdominal pain) evident within 4 weeks of screening and/or at the screening
             examination.

          -  Use of any drugs known to induce or inhibit hepatic drug metabolism within 30 days
             prior to administration of study treatment.

          -  Is sero-positive for HIV, HBV, HCV, and/or a history of delta virus hepatitis.

          -  Currently uses and/or has a history of alcohol and/or drug abuse &lt; 12 months from
             screening.

          -  Use of investigational agents or devices within 30 days prior to planned study dosing
             or current participation in an investigational study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason Lickliter, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nucleus Network Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Diamond Martin</last_name>
    <phone>+1 626 304-3400</phone>
    <email>dmartin@arrowres.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nucleus Network Ltd.</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Franich</last_name>
      <phone>1800 243 733</phone>
    </contact>
    <investigator>
      <last_name>Jason Lickliter, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 13, 2014</lastchanged_date>
  <firstreceived_date>June 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
